Alex Rodriguez TRT: The Ethics of Celebrity Prescription Disclosure

What Alex Rodriguez Has Actually Said About Testosterone Use

Rodriguez's public statements about testosterone are narrow in scope and carefully worded. In a February 2009 sit-down interview with ESPN's Peter Gammons, he confirmed using "a substance" he described as "boli," a slang term widely interpreted as Primobolan (methenolone), along with testosterone, sourced from the Dominican Republic. He said the use was from 2001 to 2003 while playing for the Texas Rangers. His direct quote: "I was young. I was stupid. I was naive." He did not characterize the use as medically supervised TRT.

After the 2013 Biogenesis investigation, MLB documents alleged Rodriguez received testosterone, human growth hormone, and other substances from the Coral Gables, Florida anti-aging clinic operated by Anthony Bosch. Rodriguez initially denied those allegations before eventually accepting a 162-game suspension (the original 211-game ban was the longest non-lifetime suspension in MLB history at the time).

What Biogenesis Records Indicated

Court documents and reporting by the Miami New Times described clinic records listing Rodriguez as receiving testosterone injections and testosterone troches (sublingual lozenges) during the 2010 to 2012 period. These records were not authenticated medical prescriptions under standard clinical protocol. The substances were not dispensed through a licensed pharmacy under a physician's written order consistent with FDA labeling.

The Distinction Between Medical TRT and PED Use

This distinction matters clinically. FDA-approved testosterone products, including testosterone cypionate injection (Depo-Testosterone) and testosterone undecanoate capsules (Jatenzo), carry labeling that restricts use to men with confirmed hypogonadism documented by two morning serum testosterone measurements below 300 ng/dL and signs or symptoms of deficiency. FDA prescribing information for testosterone products is catalogued at accessdata.fda.gov. Using testosterone without that clinical indication, or at supraphysiologic doses, constitutes off-label or illicit use, not therapeutic TRT.

No public record confirms Rodriguez was ever diagnosed with hypogonadism or evaluated under those criteria before his acknowledged use periods.

The Clinical Field of Testosterone Replacement Therapy

TRT is a legitimate, widely prescribed treatment. The American Urological Association's 2018 guideline defines hypogonadism as a serum total testosterone below 300 ng/dL combined with clinical symptoms such as reduced libido, fatigue, or depressed mood. The AUA guideline is available through the endocrine.org affiliated literature and at pubmed.ncbi.nlm.nih.gov.

Prevalence and Prescribing Trends

Approximately 2.9 million American men filled a testosterone prescription in 2019, according to a JAMA Internal Medicine analysis. That figure is cited in a population-level review indexed at pubmed.ncbi.nlm.nih.gov. Prescribing peaked around 2013 and has since stabilized after the FDA issued a safety communication in 2015 requiring manufacturers to add labeling warnings about potential cardiovascular risk and the narrow approved indication. That 2015 FDA drug safety communication is archived at fda.gov.

Cardiovascular Considerations in TRT

The cardiovascular signal has been debated for over a decade. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and pre-existing or high-risk cardiovascular disease did not increase the rate of major adverse cardiovascular events (MACE) compared to placebo over a mean 33-month follow-up. The MACE rate was 7.0% in the testosterone group versus 7.3% in the placebo group. The TRAVERSE trial is published at nejm.org. However, testosterone therapy did increase the risk of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in that trial, findings that inform clinical risk-benefit conversations.

Typical Dosing in Clinical Practice

Standard therapeutic doses of testosterone cypionate or enanthate for confirmed hypogonadism range from 50 mg to 200 mg intramuscularly every one to two weeks, or weekly subcutaneous injections in the 50 mg to 100 mg range to minimize peak-trough fluctuation. The goal is to restore serum testosterone to the mid-normal range, roughly 400 to 700 ng/dL. Dosing references appear throughout the Endocrine Society's 2018 clinical practice guideline, accessible at pubmed.ncbi.nlm.nih.gov. By contrast, supraphysiologic doping doses used in competitive sports can exceed 500 mg to 1,000 mg weekly, driving testosterone levels well above 1,500 ng/dL.

The Ethics of Disclosing Hormone Therapy: Public Figure vs. Private Patient

This is the question Rodriguez's case makes concrete. No federal statute requires any American, athlete or otherwise, to publicly disclose a lawful prescription. HIPAA's Privacy Rule protects individually identifiable health information held by covered entities, meaning healthcare providers, health plans, and their business associates. The HHS summary of HIPAA's Privacy Rule is at hhs.gov, referenced through nih.gov affiliated public health resources.

Public figures have the same medical privacy rights as anyone else. A senator, a CEO, or a retired shortstop taking lawfully prescribed TRT for documented hypogonadism has no legal obligation to announce that fact.

Where the Obligation Changes

The ethical calculus shifts under two conditions.

First, when a person has signed a contractual agreement governing substance use. MLB's Joint Drug Agreement explicitly prohibits testosterone use without a valid Therapeutic Use Exemption (TUE). A TUE requires documented medical necessity, a licensed physician's diagnosis, and approval from an independent review panel. MLB's Joint Drug Agreement, as updated, is publicly available and discussed in related labor arbitration records referenced through academic.oup.com sports law journals. Athletes subject to the JDA accepted a narrowing of their medical privacy when they agreed to those testing terms.

Second, when a public figure actively positions themselves as a health or wellness authority. Rodriguez, post-retirement, has appeared in media contexts discussing fitness, weight management, and longevity. When a recognizable figure monetizes health credibility, the audience reasonably expects disclosure of relevant personal health practices. This is not a legal requirement. It is an ethical one grounded in what communication ethicists call the non-deception principle: speakers should not create false impressions through omission when those impressions are material to the audience's trust.

Role-Model Effects and Adolescent Testosterone Use

The role-model dimension carries real clinical weight. A 2022 systematic review in the British Journal of Sports Medicine (N=9 included studies) found that adolescent exposure to media narratives normalizing PED use was associated with increased self-reported willingness to use performance-enhancing substances. That review is indexed at pubmed.ncbi.nlm.nih.gov. Anabolic-androgenic steroid use in adolescents carries documented risks including premature epiphyseal closure (early growth plate fusion), suppression of the hypothalamic-pituitary-gonadal (HPG) axis, and adverse lipid changes. Adolescent AAS risks are reviewed at pubmed.ncbi.nlm.nih.gov in the 2021 NIDA-supported literature.

Among high school students surveyed in the CDC's 2019 Youth Risk Behavior Survey, approximately 3.3% of male students reported lifetime use of anabolic steroids without a prescription. The YRBS data are accessible through cdc.gov. That figure has persisted across survey cycles despite decades of anti-doping messaging.

How Anti-Doping Policy Structures Disclosure

MLB's drug testing program operates under a consent-based disclosure model. Athletes consent to testing; results are shared with the league and union under confidentiality provisions. Violations become public when the commissioner's office announces a suspension, as happened with Rodriguez in 2013.

The Therapeutic Use Exemption Process

A TUE is the formal mechanism through which a legitimately hypogonadal athlete can use prescribed testosterone without a doping violation. The process mirrors World Anti-Doping Agency (WADA) standards. A physician must document that the athlete meets clinical criteria for hypogonadism, that withholding treatment would cause significant health harm, and that no permitted alternative exists. WADA's International Standard for TUEs is catalogued through the anti-doping literature at pubmed.ncbi.nlm.nih.gov.

MLB records do not indicate Rodriguez held an approved TUE during either his 2001 to 2003 self-disclosed use period or the Biogenesis-era allegations. That absence is the crux of the policy violation. It does not prove he was not hypogonadal; it proves he did not pursue the compliant pathway.

Post-Career Testosterone Use and Disclosure

Once Rodriguez retired from professional baseball in August 2016, he was no longer subject to MLB's JDA testing program. Any testosterone therapy he may use now exists entirely in the domain of private medical care. No sports body, no regulatory agency, and no statute creates a disclosure requirement. His public silence on current hormone use, if any exists, is legally and clinically unremarkable.

A Clinical Framework for Evaluating Celebrity TRT Claims

When a public figure's name is attached to testosterone or TRT, a structured evaluation helps separate clinical fact from inference:

Step 1. Identify the source of the claim. Is it self-disclosure, a leaked document, a media report, or inference from physical appearance? Rodriguez's 2009 ESPN statement is self-disclosure. The Biogenesis allegations were document-based and later accepted via suspension.

Step 2. Determine the regulatory context at the time. Was the person subject to a drug-testing agreement? An active MLB player is. A retired executive is not.

Step 3. Assess clinical plausibility. Men in their 30s and 40s show a mean testosterone decline of approximately 1% to 2% per year. That decline rate is documented in the Massachusetts Male Aging Study, cited at pubmed.ncbi.nlm.nih.gov. A 45-year-old man with symptoms of hypogonadism seeking TRT is clinically unremarkable. The question is whether the use is therapeutic (confirmed deficiency, normal dosing, licensed physician, licensed pharmacy) or supraphysiologic.

Step 4. Separate moral judgment from clinical fact. Using testosterone above physiologic doses to gain athletic advantage is prohibited under signed contracts and produces documented health risks. Using FDA-approved testosterone at therapeutic doses under physician supervision for documented hypogonadism is standard medical care. These are not the same act, and conflating them harms patients who need legitimate treatment.

Step 5. Apply proportionate disclosure expectations. Athletes under drug-testing agreements have accepted contractual disclosure mechanisms (TUE). Wellness influencers who build audiences around health credibility carry an ethical (not legal) duty of transparency. Private individuals carry no duty at all.

What Physicians and Ethicists Say

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend testosterone therapy for men with symptomatic androgen deficiency to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density." That guideline is published at pubmed.ncbi.nlm.nih.gov. That clinical position frames TRT as standard care, not a controversial intervention, when used appropriately.

From a bioethics perspective, the principle of veracity in medical communication holds that healthcare providers should not deceive patients. Extended to public health communication, a broader version of that principle suggests that figures with health authority should not create misleading impressions. Dr. Norman Fost, a prominent sports medicine ethicist at the University of Wisconsin, has written that the moral status of performance-enhancing substance use hinges primarily on harm to others, particularly youth who model behavior after prominent athletes. Dr. Fost's work on PED ethics appears in the bioethics literature indexed at pubmed.ncbi.nlm.nih.gov.

That harm-to-others lens explains why the Rodriguez case retains relevance beyond the suspension itself. The documented willingness of adolescents to use testosterone when they perceive it as normalized by admired athletes means transparency from former and current public figures carries downstream clinical consequences.

TRT in Retired Athletes: What the Physiology Looks Like

Retired high-performance athletes sometimes present to testosterone clinics with genuinely suppressed HPG axes. Years of anabolic steroid use can cause secondary hypogonadism through prolonged suppression of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), leaving endogenous testosterone production blunted even after cessation. The mechanism of HPG axis suppression by exogenous androgens is reviewed at pubmed.ncbi.nlm.nih.gov.

Distinguishing Primary from Secondary Hypogonadism

A thorough clinical workup matters. Primary hypogonadism (testicular failure) presents with low testosterone and elevated LH/FSH. Secondary hypogonadism (pituitary or hypothalamic dysfunction, which steroid-induced suppression mimics) presents with low testosterone and low or inappropriately normal LH/FSH. The AUA and Endocrine Society both require measurement of LH and FSH to classify hypogonadism; the AUA guideline is at pubmed.ncbi.nlm.nih.gov.

A retired athlete presenting with steroid-induced secondary hypogonadism may be a legitimate TRT candidate, or may be a candidate for clomiphene citrate or human chorionic gonadotropin (hCG) stimulation to restart endogenous production, depending on the degree of axis suppression and fertility goals. Clomiphene citrate 25 mg to 50 mg daily has shown efficacy in raising testosterone in secondary hypogonadism in multiple trials. Clomiphene for male hypogonadism is reviewed at pubmed.ncbi.nlm.nih.gov.

Recovery Timelines After Androgen Cessation

The HPG axis can take 6 to 18 months to partially recover after long-term anabolic steroid use. For men with prolonged high-dose use histories, full recovery may never occur. Recovery of HPG axis function post-AAS is documented in a 2020 review at pubmed.ncbi.nlm.nih.gov. This means some former PED users develop genuine, documentable hypogonadism as a direct consequence of prior misuse, creating a clinical situation where the same person who misused testosterone may later qualify for medically supervised TRT.

That irony does not change the clinical indication. If a man meets the diagnostic criteria, is symptomatic, and has two morning testosterone readings below 300 ng/dL, he qualifies for treatment regardless of how his deficiency developed.